Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis

Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes

(2013) D. M. Rabi et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Comparative Tolerability and Harms of Individual Statins

(2013) Huseyin Naci et al.  

Termination of Clozapine Treatment Due to Medical Reasons

(2013) Jimmi Nielsen et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness

(2013) Gail L. Daumit et al.   NEW ENGLAND JOURNAL OF MEDICINE

A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls

(2013) Davy Vancampfort et al.   World Psychiatry

Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth

(2013) William V. Bobo et al.   JAMA Psychiatry

Bridging the gap from evidence to policy and practice: Reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication

(2012) Valsamma Eapen et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis

(2012) Cherrie A Galletly et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

People living with psychotic illness in 2010: The second Australian national survey of psychosis

(2012) Vera A Morgan et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials

(2012) Elena Bonfioli et al.   BMC Psychiatry

Diabetes and hypertension: the bad companions

(2012) Ele Ferrannini et al.   LANCET

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)

(2011) T. Scott Stroup et al.   AMERICAN JOURNAL OF PSYCHIATRY

Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis

(2011) Debra L. Foley et al.   ARCHIVES OF GENERAL PSYCHIATRY

The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives

(2011) Lei Chen et al.   Nature Reviews Endocrinology

Endogenic and Iatrogenic Diabetes Mellitus in Drug-naïve Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm

(2011) Dan Cohen et al.   NEUROPSYCHOPHARMACOLOGY

Changing the odds. What do we learn from prevention studies targeted at people with a positive family history of type 2 diabetes?

(2011) Wieke H. Heideman et al.   Primary Care Diabetes

Patterns of Antipsychotic Medication Use in Australia 2002–2007

(2010) Samantha A. Hollingworth et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

(2010) C.U. Correll   EUROPEAN PSYCHIATRY

Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients

(2010) Jimmi Nielsen et al.   NEUROPSYCHOPHARMACOLOGY

Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders

(2009) Mario Álvarez-Jiménez et al.   CNS DRUGS

The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study

(2009) Marianne Ulcickas Yood et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Antipsychotics, Glycemic Disorders, and Life-Threatening Diabetic Events: A Bayesian Data-Mining Analysis of the FDA Adverse Event Reporting System (1968-2004)

(2008) William DuMouchel et al.   Annals of Clinical Psychiatry

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis

(2008) M. Smith et al.   BRITISH JOURNAL OF PSYCHIATRY